Exploring anti-liver cancer targets and mechanisms of oxyresveratrol: in silico and verified findings

References

• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379(9822):1245–1255.
   PubMed Web of Science ®Google Scholar
• Zuo TT, Zheng RS, Zhang SW, et al. Incidence and mortality of liver cancer in China in 2011. Chin J Cancer. 2015;34(3):508–513.
   PubMedGoogle Scholar
• Deng W, Long L, Tang XY, et al. Anisotropic patterns of liver cancer prevalence in Guangxi in Southwest China: is local climate a contributing factor? Asian Pac J Cancer Prev. 2015;16(8):3579–3586.
   PubMedGoogle Scholar
• Zhou R, Liu M, Liang X, et al. Clinical features of aflatoxin B1-exposed patients with liver cancer and the molecular mechanism of aflatoxin B1 on liver cancer cells.Environ Toxicol Pharmacol. 2019;71:103225.
   PubMed Web of Science ®Google Scholar
• Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314
   PubMed Web of Science ®Google Scholar
• Rimassa L, Danesi R, Pressiani T, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev. 2019;77:20–28.
   PubMed Web of Science ®Google Scholar
• Liao YH, Lin CC, Lai HC, et al. Adjunctive traditional Chinese medicine therapy improves survival of liver cancer patients. Liver Int. 2015;35(12):2595–2602.
   PubMed Web of Science ®Google Scholar
• Zhou R, Wu K, Su M, et al. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma. Environ Toxicol Pharmacol. 2019;70:103200.
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhou R, Liang X, et al. Pharmacological targets and molecular mechanisms of plumbagin to treat colorectal cancer: a systematic pharmacology study. Eur J Pharmacol. 2020;881:173227.
   PubMed Web of Science ®Google Scholar
• Singh AP, Singh R, Verma SS, et al. Health benefits of resveratrol: evidence from clinical studies. Med Res Rev. 2019 Sep;39(5):1851–1891.
   PubMed Web of Science ®Google Scholar
• Carter LG, D’Orazio JA, Pearson KJ. Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer. 2014;21(3):209–225.
   PubMed Web of Science ®Google Scholar
• Li R, Ma X, Song Y, et al. Anti-colorectal cancer targets of resveratrol and biological molecular mechanism: analyses of network pharmacology, human and experimental data. J Cell Biochem. 2019;120(7):11265–11273.
   PubMed Web of Science ®Google Scholar
• Li R, Song Y, Ji Z, et al. Pharmacological biotargets and the molecular mechanisms of oxyresveratrol treating colorectal cancer: network and experimental analyses. Biofactors. 2020;46(1):158–167.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ren W, Bai Y, et al. Oxyresveratrol prevents murine H22 hepatocellular carcinoma growth and lymph node metastasis via inhibiting tumor angiogenesis and lymphangiogenesis. J Nat Med. 2018;72(2):481–492.
   PubMed Web of Science ®Google Scholar
• Li R, Li Y, Liang X, et al. Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets. Brief Bioinform. 2021;22(2):1279–1290.
   PubMed Web of Science ®Google Scholar
• Li R, Guo C, Li Y, et al. Therapeutic target and molecular mechanism of vitamin C-treated pneumonia: a systematic study of network pharmacology. Food Funct. 2020;11(5):4765–4772.
   PubMed Web of Science ®Google Scholar
• Pan Q, Zhou R, Su M, et al. The effects of plumbagin on pancreatic cancer: a mechanistic network pharmacology approach. Med Sci Monit. 2019;25:4648–4654.
   PubMed Web of Science ®Google Scholar
• Li R, Wu K, Li Y, et al. Revealing the targets and mechanisms of vitamin A in the treatment of COVID-19. Aging (Albany NY). 2020;12(15):15784–15796.
   PubMedGoogle Scholar
• Li R, Wu K, Li Y, et al. Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses. Brief Bioinform. 2021;22(2):1161–1174.
   PubMed Web of Science ®Google Scholar
• Qin X, Huang C, Wu K, et al. Anti-coronavirus disease 2019 (COVID-19) targets and mechanisms of puerarin. J Cell Mol Med. 2021;25(2):677–685.
   PubMed Web of Science ®Google Scholar
• Li R, Guo C, Li Y, et al. Functional benefit and molecular mechanism of vitamin C against perfluorooctanesulfonate-associated leukemia. Chemosphere 2021;263:128242.
   PubMed Web of Science ®Google Scholar
• Li R, Guo C, Li Y, et al. Therapeutic targets and signaling mechanisms of vitamin C activity against sepsis: a bioinformatics study. Brief Bioinform. 2020 May 11; bbaa079. 10.1093/bib/bbaa079.
   Web of Science ®Google Scholar
• Li R, Huang C, Ho JCH, et al. The use of glutathione to reduce oxidative stress status and its potential for modifying the extracellular matrix organization in cleft lip. Free Radic Biol Med. 2021;164:130–138.
   PubMed Web of Science ®Google Scholar
• Nong Y, Liang Y, Liang X, et al. Pharmacological targets and mechanisms of calycosin against meningitis. Aging (Albany NY). 2020;12(19):19468–19492.
   PubMedGoogle Scholar
• Li J, Guo C, Lu X, et al. Anti-colorectal cancer biotargets and biological mechanisms of puerarin: study of molecular networks. Eur J Pharmacol. 2019;858:172483.
   PubMed Web of Science ®Google Scholar
• Nong Y, Liang Y, Liang X, et al. Pharmacological targets and mechanisms of calycosin against meningitis. Aging (Albany NY). 2020;12(19):19468–19492.
   PubMedGoogle Scholar
• Yu S, Wu K, Liang Y, et al. Therapeutic targets and molecular mechanism of calycosin for the treatment of cerebral ischemia/reperfusion injury. Aging (Albany NY). 2021;13(12):16804–16815.
   PubMedGoogle Scholar
• Li R, Huang X, Liang X, et al. Integrated omics analysis reveals the alteration of gut microbe-metabolites in obese adults. Brief Bioinform. 2020;bbaa165. 10.1093/bib/bbaa165.
   Web of Science ®Google Scholar
• Li R, Guo C, Lin X, et al. Integrative omics analyses uncover the mechanism underlying the immunotoxicity of perfluorooctanesulfonate in human lymphocytes. Chemosphere 2020;256:127062.
   PubMed Web of Science ®Google Scholar
• Xu X, Guo C, Liang X, et al. Potential biomarker of fibroblast growth factor 21 in valproic acid-treated livers. Biofactors 2019;45(5):740–749.
   PubMed Web of Science ®Google Scholar
• Li R, Ma X, Song Y, et al. Anti-colorectal cancer targets of resveratrol and biological molecular mechanism: analyses of network pharmacology, human and experimental data. J Cell Biochem. 2019;120(7):11265–11273.
   PubMed Web of Science ®Google Scholar
• Kulkoyluoglu-Cotul E, Arca A, Madak-Erdogan Z. Crosstalk between estrogen signaling and breast cancer metabolism. Trends Endocrinol Metab. 2019;30(1):25–38.
   PubMed Web of Science ®Google Scholar
• Saha T, Makar S, Swetha R, et al. Estrogen signaling: an emanating therapeutic target for breast cancer treatment. Eur J Med Chem. 2019;177:116–143.
   PubMed Web of Science ®Google Scholar
• Carausu M, Bidard FC, Callens C, et al. ESR1 mutations: a new biomarker in breast cancer. Expert Rev Mol Diagn. 2019;19(7):599–611.
   PubMed Web of Science ®Google Scholar
• Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer 2019;125(21):3714–3728.
   PubMed Web of Science ®Google Scholar
• Zhang H, Deng T, Liu R, et al. Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat Commun. 2017; 8(1): 15016.
   PubMedGoogle Scholar